Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336803 · ClinicalTrials.gov registry record · Phase 2
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
A Phase 2 study, sponsored by Heike E Daldrup-Link.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01336803: Completed Phase 2 study, sponsored by Heike E Daldrup-Link.
NCT01336803 is a Phase 2 study that has completed, run by Heike E Daldrup-Link. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01336803, a Phase 2 study, has completed, sponsored by Heike E Daldrup-Link.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.
Primary Outcome
Differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI) was assessed as the difference of mean T2 \* relaxation time of bone sarcoma and osteomyelitis subjects. The outcome is reported as the difference of the mean T2 \* values, with standard deviation.
Interventions
- DRUG Feraheme
- PROCEDURE Magnetic Resonance Imaging (MRI) scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-08 |
| Est. Completion | 2023-10 |
| Phase | Phase 2 |
What the finished NCT01336803 record still lists
NCT01336803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Feraheme is the first listed.
NCT01336803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01336803 about?
NCT01336803 is a clinical study titled "Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI". This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correct...
What is the current status of trial NCT01336803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2011-08. Estimated completion is 2023-10.
What interventions are being tested in trial NCT01336803?
The interventions under investigation include: Feraheme (DRUG), Magnetic Resonance Imaging (MRI) scan (PROCEDURE).
Who is sponsoring clinical trial NCT01336803?
This trial is sponsored by Heike E Daldrup-Link, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01336803's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia